How to access Pluvicto from the UAE, the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Emirati patient with metastatic castration-resistant prostate cancer (mCRPC) may receive a prescription for Pluvicto (lutetium Lu-177 vipivotide tetraxetan) from their treating oncologist after progression on standard hormonal and taxane-based therapies. Pluvicto is FDA-approved, manufactured in the United States, and is a recognised option for PSMA-positive mCRPC. In the Kingdom of the UAE, Pluvicto is not yet broadly registered for routine hospital-pharmacy dispensing, which is why your oncologist may be coordinating a named-patient import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and how quotes work, and where Reserve Meds fits in.
Ask about Pluvicto in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Pluvicto is a radioligand therapy that delivers targeted beta-radiation to PSMA-expressing prostate cancer cells. Eligibility typically requires PSMA-PET imaging confirmation, documented prior therapy consistent with FDA labeling, and management by a medical oncologist working alongside a licensed nuclear medicine service. The manufacturer is Novartis. Because Pluvicto is a short-half-life radiopharmaceutical, it must be shipped against a tight decay calendar and can only be administered at a facility licensed to handle radioactive therapeutics. Your oncologist will confirm PSMA eligibility and sequencing against your overall treatment plan.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Pluvicto legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, in coordination with the administering hospital's nuclear medicine and radiation-safety departments. The UAE has a mature named-patient mechanism that has supported cross-border access to specialised oncology and rare-disease products for many years.
The MoHAP named-patient route allows an Emirati-licensed physician to request import of a medicine that is not locally registered when: (a) the medicine has been approved by a recognised reference authority (FDA qualifies), (b) there is no clinically equivalent locally registered alternative, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the administering facility. Applications are reviewed by the MoHAP Drug Sector.
For Pluvicto specifically, the pathway additionally requires coordination with the Nuclear and Radiological Regulatory Commission and with the hospital's radiopharmacy. Administration is only permitted at facilities holding the appropriate radiation-handling licensure.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Pluvicto is a clinical one. Your oncologist will document PSMA-PET findings, prior line history, and a written clinical rationale.
- Nuclear medicine facility identification. A licensed nuclear medicine unit must accept the case. Several tertiary centres in Riyadh, Jeddah, and the Eastern Province hold the relevant licensure.
- MoHAP named-patient application. Your physician or the hospital's importing pharmacy files an application with MoHAP, including clinical rationale, patient reference, product details, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from the manufacturer's authorised distribution chain. Because of the radioactive decay calendar, the shipping window is booked to match your administration date.
- Radiation-compliant shipment. The product moves with radiation-handling, temperature, and chain-of-custody documentation end to end.
- Arrival and administration. The licensed facility receives the dose and administers under your oncologist's care. Subsequent cycles are scheduled, typically at six-week intervals.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis, prior therapies, and Pluvicto as the indicated next step
- Verification of their UAE medical licence (SCFHS / MOH)
- Identification of the administering nuclear medicine facility and its radiation-handling licence
- Patient identifier (an anonymised patient reference is preferred for privacy)
- The planned administration cycle (typically four to six doses, six weeks apart, per FDA labeling)
Reserve Meds provides a physician documentation kit that bundles the templates most MoHAP reviewers expect to see. Your oncologist does not need prior named-patient experience; the kit is designed to make a first-time application straightforward.
Costs and timing
Medicine price: quote on request. You get a written quote for your case before you commit. Radiation-compliant logistics, MoHAP documentation handling, and coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
We give you a written timeline estimate for your case before you commit. Subsequent cycles are generally faster once the pathway is established and the administering facility is familiar with the case.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
A brief culturally-aware note: Ramadan and Hajj seasons can affect scheduling across the UAE tertiary centres. Our team coordinates cycle timing with your family's preferences and your hospital's calendar.
Reserve Meds's role
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Pluvicto specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory documentation package for your physician and for MoHAP review.
- Logistics. Radiation-compliant and temperature-controlled shipment coordination.
- Dedicated case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist and the administering nuclear medicine facility.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient framework with appropriate documentation and a licensed administering facility. This pathway has been used routinely across oncology and rare disease for many years. See our trust and compliance page for our methodology.
What if my oncologist has not done this before? Named-patient import is an institutional process your oncologist's hospital will have encountered, even if the individual physician has not. Our documentation kit closes the gap for first-time applicants.
What if the shipment is delayed? Pluvicto's short half-life means scheduling precision matters. Our protocol builds in buffer time. In the rare event of a delay that causes the product to decay below usable activity, we re-source at our cost per service terms and reschedule with the facility.
What about adverse-event reporting? Your oncologist and the administering team manage clinical care and adverse-event reporting. We document and forward events to the manufacturer as part of pharmacovigilance obligations when requested.
Will private insurance cover this? Cash-pay is the default. Some UAE private insurers reimburse named-patient imports on a case-by-case basis; we supply documentation for your submission but do not process insurance claims directly.
Next step
For Pluvicto coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-04-23.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Pluvicto in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Pluvicto for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Pluvicto in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Pluvicto. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Pluvicto in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Pluvicto to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Pluvicto to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Pluvicto in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Pluvicto in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.